St. Jude Warning Letter Updates: CRM Facility Reinspected; Neuro Plant Awaits FDA Visit
This article was originally published in The Gray Sheet
Executive Summary
St. Jude updated the status of its efforts to resolve FDA warnings letters linked to its cardiac rhythm management and neuromodulation divisions during its first-quarter earnings call on April 16.
You may also be interested in...
Challenges With ICD Leads Are Under Control, St. Jude Tells Investors
The company was prepared for FDA’s recent warning letter, executives said on an earnings call. But the scrutiny is not over, analysts suggest.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.